Acrotech Company Profile

What is the competitive landscape for ACROTECH

ACROTECH has six approved drugs.

There are twelve US patents protecting ACROTECH drugs.

There are one hundred and seventy-nine patent family members on ACROTECH drugs in thirty-four countries and five supplementary protection certificates in four countries.

Summary for Acrotech

International Patents:	179
US Patents:	12
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Acrotech

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes	6,888,027		Y	Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes	10,864,183		Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes	9,493,582		Y
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009		RX	Yes	Yes	8,299,078
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-003	Apr 29, 2011		DISCN	Yes	No
Acrotech Biopharma	KHAPZORY	levoleucovorin	POWDER;INTRAVENOUS	211226-001	Oct 19, 2018		RX	Yes	Yes	11,541,012		Y
Acrotech Biopharma	KHAPZORY	levoleucovorin	POWDER;INTRAVENOUS	211226-002	Oct 19, 2018		DISCN	Yes	No	11,541,012		Y

Expired US Patents for Acrotech

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009	6,028,071
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009	6,028,071
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	5,543,152
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	7,887,836
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	6,723,338
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	5,741,516
Acrotech	MARQIBO KIT	vincristine sulfate	INJECTABLE, LIPOSOMAL;INTRAVENOUS	202497-001	Aug 9, 2012	7,247,316

Paragraph IV (Patent) Challenges for ACROTECH drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	50 mg/vial		2013-12-19
	Injection	500 mg/vial		2018-07-03
	Injection	10 mg/mL, 17.5 mL vial and 25 mL vial		2011-10-26
	Injection	20 mg/mL and 40 mg/2 mL		2013-09-24
	Injection	50 mg/vial		2017-09-08

International Patents for Acrotech Drugs

Country	Patent Number	Estimated Expiration
Japan	2008540499
Mexico	353603
New Zealand	576849
Singapore	11201503089W
Spain	2540204
World Intellectual Property Organization (WIPO)	2010138920
World Intellectual Property Organization (WIPO)	2014066274

Supplementary Protection Certificates for Acrotech Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2701720	122023000007	Germany		PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817
2701720	23C1000	France		PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720	3/2023	Austria		PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818
2701720	CA 2022 00054	Denmark		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720	CR 2022 00054	Denmark		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Acrotech
• Acrotech Biopharma

Acrotech Biopharma: A Rising Star in the Pharmaceutical Competitive Landscape

In the ever-evolving world of pharmaceuticals, Acrotech Biopharma has emerged as a noteworthy player, carving out a unique position in the competitive landscape. Founded in 2018, this relatively young company has quickly made its mark, particularly in the oncology and hematology sectors. Let's dive into Acrotech's market position, strengths, and strategic insights that are shaping its trajectory in the pharmaceutical industry.

The Birth of Acrotech Biopharma

Acrotech Biopharma Inc., a subsidiary of Aurobindo Pharma USA, was established with a clear mission: to develop and commercialize innovative proprietary medications[1]. From its inception, the company set its sights on addressing unmet medical needs and delivering value to patients and healthcare stakeholders alike.

A Strategic Acquisition

Acrotech's journey took a significant turn in 2019 when it acquired seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals for $300 million[3]. This bold move instantly positioned Acrotech as a leader in specific therapeutic areas, particularly in peripheral T-cell lymphoma (PTCL)[9].

"We are excited to jump-start our mission of helping cancer patients across the globe by delivering clinically differentiated medications and leveraging strategic partnerships," said Dr. Ashish Anvekar, President of Acrotech[6].

Acrotech's Market Position

In a relatively short time, Acrotech has established itself as a significant player in the oncology and hematology markets. The company's focus on "diamonds-in-the-rough" - drugs with improved efficacy and/or safety over current treatments - has set it apart from competitors[9].

Product Portfolio

Acrotech currently markets five injectable oncology brands in the USA, with a strong presence in PTCL treatment[2]. Its product lineup includes well-recognized names such as Folotyn, Beleodaq, and Evomela, among others[3].

Global Reach

While Acrotech's primary market is the USA, the company has expanded its reach globally through strategic partnerships. These collaborations cover major markets including the EU, Canada, Japan, China, and Latin America[2].

Acrotech's Competitive Advantages

Several factors contribute to Acrotech's competitive edge in the pharmaceutical landscape:

1. Focused Strategy

Acrotech's strategy of targeting niche areas within oncology and hematology allows it to concentrate its resources effectively. This focused approach enables the company to compete with larger pharmaceutical giants in specific therapeutic areas.

2. Robust Commercial Infrastructure

The acquisition from Spectrum Pharmaceuticals not only brought valuable products but also an experienced commercial team. This infrastructure provides Acrotech with the capability to effectively market and distribute its products[6].

3. Patient-Centric Approach

Acrotech's commitment to patient care is evident in initiatives like the STAR program, which provides patient assistance for those who meet certain criteria[7]. This patient-focused approach enhances the company's reputation and builds brand loyalty.

Competitive Landscape Analysis

To understand Acrotech's position, it's crucial to examine the broader pharmaceutical competitive landscape:

Key Players

The pharmaceutical industry is dominated by giants like Pfizer, Johnson & Johnson, Novartis, and Merck & Co[4]. These companies have vast resources for R&D and global marketing capabilities.

Market Trends

Several trends are shaping the pharmaceutical industry:

1. Personalized medicine
2. Digital health integration
3. Increasing focus on rare diseases
4. Biosimilars and generics
5. Emphasis on value-based care

Acrotech's Position

In this landscape, Acrotech has positioned itself as a specialist in oncology and hematology, with a particular focus on rare and uncommon diseases. This niche strategy allows Acrotech to compete effectively in specific areas without directly challenging the industry giants across all therapeutic categories.

Strategic Insights

Acrotech's strategy offers several insights for success in the pharmaceutical industry:

1. Niche Focus

By concentrating on specific therapeutic areas, Acrotech has been able to build expertise and a strong market position rapidly. This strategy can be particularly effective for smaller companies competing against industry giants.

2. Strategic Acquisitions

Acrotech's acquisition of Spectrum's portfolio demonstrates how strategic purchases can quickly establish a company's market presence and provide a foundation for growth.

3. Global Partnerships

Acrotech's approach to global expansion through partnerships allows it to extend its reach without the full cost and risk of establishing operations in each market.

4. Patient-Centric Programs

Initiatives like the STAR program show how pharmaceutical companies can build goodwill and address access issues, potentially leading to increased adoption and loyalty.

Challenges and Opportunities

While Acrotech has made significant strides, it faces several challenges and opportunities:

Challenges

1. Competition from larger pharmaceutical companies
2. Regulatory hurdles in drug development and approval
3. Pricing pressures in the healthcare industry
4. Need for continuous innovation to maintain market position

Opportunities

1. Expansion into new therapeutic areas within oncology and hematology
2. Development of biosimilars and generics
3. Leveraging digital health technologies for patient care and drug development
4. Exploring emerging markets for growth

Future Outlook

Acrotech's future looks promising, with plans to expand its portfolio through both internal R&D and strategic acquisitions. The company is also preparing to commercialize a biosimilar pipeline in the immuno-oncology space through its sister company CuraTeq[2].

As the pharmaceutical landscape continues to evolve, Acrotech's focused strategy and patient-centric approach position it well for continued growth and success.

Key Takeaways

1. Acrotech Biopharma has quickly established itself as a significant player in oncology and hematology since its founding in 2018.
2. The company's strategic acquisition of seven FDA-approved products from Spectrum Pharmaceuticals was a game-changer.
3. Acrotech's focused strategy on niche areas within oncology allows it to compete effectively with larger pharmaceutical companies.
4. The company's patient-centric approach, including programs like STAR, enhances its market position.
5. Acrotech's global partnerships and plans for biosimilar development indicate potential for future growth.
6. While facing challenges such as competition and regulatory hurdles, Acrotech's strategic positioning offers numerous opportunities for expansion and innovation.

FAQs

1. Q: What is Acrotech Biopharma's primary focus? A: Acrotech Biopharma primarily focuses on developing and commercializing innovative medications in oncology and hematology, with a particular emphasis on rare and uncommon diseases.

2. Q: How did Acrotech quickly establish its market presence? A: Acrotech rapidly established its market presence through the strategic acquisition of seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in 2019.

3. Q: What sets Acrotech apart from its competitors? A: Acrotech differentiates itself through its focused strategy on niche areas within oncology, its patient-centric approach, and its emphasis on "diamonds-in-the-rough" - drugs with improved efficacy or safety over current treatments.

4. Q: How is Acrotech expanding globally? A: Acrotech is expanding globally through strategic partnerships covering major markets including the EU, Canada, Japan, China, and Latin America.

5. Q: What are Acrotech's plans for future growth? A: Acrotech plans to expand its portfolio through internal R&D and strategic acquisitions, and is preparing to commercialize a biosimilar pipeline in the immuno-oncology space through its sister company CuraTeq.

Sources cited: [1] https://acrotechbiopharma.com [2] https://www.aurobindo.com/our-business/acrotech [3] https://acrotechbiopharma.com/acrotech-biopharma-to-buy-seven-drugs-from-spectrum-for-300m/ [4] https://canvasbusinessmodel.com/blogs/competitors/pfizer-competitive-landscape [5] https://rocketreach.co/acrotech-biopharma-inc-profile_b45313e0fc83bcd1 [6] https://acrotechbiopharma.com/acquisition-for-an-upfront-purchase-price-of-160-million-in-cash-plus-up-to-140-million-on-achieving-regulatory-and-sales-based-milestones/ [7] https://acrotechpatientaccess.com/patient-assistance-program/ [9] https://www.biospace.com/a-platform-for-hope-in-the-face-of-rare-and-uncommon-diseases